Aim: Research suggests that Alzheimer’s disease (AD) is heterogeneous with numerous subtypes. Through a proprietary interactive ML system, several underlying biological mechanisms associated with AD pathology were uncovered. This paper is an introduction to emerging analytic efforts that can more precisely elucidate the heterogeneity of AD. Methods: A public AD data set (GSE84422) consisting of transcriptomic data of postmortem brain samples from healthy controls (n = 121) and AD (n = 380) subjects was analyzed. Data were processed by an artificial intelligence platform designed to discover potential drug repurposing candidates, followed by an interactive augmented intelligence program. Results: Using perspective analytics, six perspectiv...
BackgroundAlzheimer’s disease (AD) is an age-associated neurodegenerative disease, and the currently...
Introduction: Genome-wide association studies (GWAS) for late onset Alzheimer\u27s disease (AD) may ...
Knowledge about the molecular mechanisms driving Alzheimer's disease (AD) is still limited. To learn...
Alzheimer’s disease (AD) is the most common cause of dementia. It is characterized by loss of memor...
Alzheimer’s disease (AD) is a complex multifactorial disorder with poorly characterized pathogenesis...
Alzheimer’s disease (AD) is a clinically heterogeneous neurodegenerative disease with a strong genet...
INTRODUCTION: Genetics and omics studies of Alzheimer’s disease and other dementia subtypes enhance ...
Alzheimer’s disease (AD) affects millions worldwide, but there are no effective treatments. AD is de...
Decades of experimental and clinical research have contributed to unraveling many mechanisms in the ...
INTRODUCTION: Machine learning models were used to discover novel disease trajectories for autosomal...
Alzheimer’s disease (AD) is a devastating, progressive neurodegenerative disorder that results in de...
Alzheimer\u27s disease (AD) has become a common disease of the elderly for which no cure currently e...
The ideal outcome for medical research is the ability to provide personalised treatment for the popu...
BackgroundAlzheimer’s disease (AD) is an age-associated neurodegenerative disease, and the currently...
There are still no effective treatments to prevent, halt, or reverse Alzheimer's disease, but resear...
BackgroundAlzheimer’s disease (AD) is an age-associated neurodegenerative disease, and the currently...
Introduction: Genome-wide association studies (GWAS) for late onset Alzheimer\u27s disease (AD) may ...
Knowledge about the molecular mechanisms driving Alzheimer's disease (AD) is still limited. To learn...
Alzheimer’s disease (AD) is the most common cause of dementia. It is characterized by loss of memor...
Alzheimer’s disease (AD) is a complex multifactorial disorder with poorly characterized pathogenesis...
Alzheimer’s disease (AD) is a clinically heterogeneous neurodegenerative disease with a strong genet...
INTRODUCTION: Genetics and omics studies of Alzheimer’s disease and other dementia subtypes enhance ...
Alzheimer’s disease (AD) affects millions worldwide, but there are no effective treatments. AD is de...
Decades of experimental and clinical research have contributed to unraveling many mechanisms in the ...
INTRODUCTION: Machine learning models were used to discover novel disease trajectories for autosomal...
Alzheimer’s disease (AD) is a devastating, progressive neurodegenerative disorder that results in de...
Alzheimer\u27s disease (AD) has become a common disease of the elderly for which no cure currently e...
The ideal outcome for medical research is the ability to provide personalised treatment for the popu...
BackgroundAlzheimer’s disease (AD) is an age-associated neurodegenerative disease, and the currently...
There are still no effective treatments to prevent, halt, or reverse Alzheimer's disease, but resear...
BackgroundAlzheimer’s disease (AD) is an age-associated neurodegenerative disease, and the currently...
Introduction: Genome-wide association studies (GWAS) for late onset Alzheimer\u27s disease (AD) may ...
Knowledge about the molecular mechanisms driving Alzheimer's disease (AD) is still limited. To learn...